Who is affected by this change?

This affects Independence Blue Cross Wound Care, Podiatry, General Surgery, Plastic Surgery, Vascular Surgery providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 1, 2026.

What do I need to do?

Already effective 10/01/2026: Billing team should confirm that Medicare Advantage claims for bioengineered skin substitutes follow the revised policy. For chronic lower extremity wounds, the chart must document a skin deficit of at least 1.0 cm2, a clean wound without infection, necrosis or exposed bone, adequate circulation (for example ABI of at least 0.60 or toe pressure above 30 mm Hg), and a failed response to appropriate wound care using the CMS definition, with the diagnosis and wound history recorded so the claim matches the criteria. Providers and front desk staff should be told that skin substitutes used for acute wounds, post-Mohs, or post-surgical use are treated as experimental or investigational under this policy. In charge entry, add the newly eligible HCPCS codes (for example A2005, A2006, the Q4 series, and C9358 to C9364) only for products listed under the applicable indication, and flag CPT 1044T through 1049T as experimental or investigational rather than submitting them as covered. Also update the code set for the revised codes A2040 through A2045 and Q4298 and Q4299. Biobrane glove is now listed as medically necessary for second- and third-degree burns, so update the burn indication in the charge set-up. The HCPCS G0681 through G0684 effective date was revised to 01/01/2026, which has already passed, so confirm those charges use current dates. Watch for Independence Blue Cross's next medical policy bulletin.

← Back to list

Independence Blue CrossMedicare Advantage · Billing Codes · Medical Policy · Wound Care, Podiatry, General Surgery +2 moreHigh impact

MA11.015ah, Bioengineered Skin Substitutes

Q: Which billing codes are affected?

The following codes are affected: A2001, A2002, A2004, A2005, A2006, A2007, A2020, A2029, A2040, A2041, A2042, A2043, A2045, A2046, A2047, A2048, A2049, A2050, C1832, C9358, C9360, C9364, Q4130, Q4138, Q4142, Q4143, Q4150, Q4207, Q4212, Q4213, Q4223, Q4226, Q4233, Q4240, Q4241, Q4242, Q4243, Q4285, Q4286, Q4298, Q4299, Q4313, Q4315, Q4316, Q4323, Q4324, Q4334, Q4335, Q4343, Q4346, Q4347, Q4348, Q4349, Q4350, Q4351, Q4352, Q4353, Q4360, Q4369, Q4391, G0681, G0682, G0683, G0684, 15011, 15012, 15013, 15014.

Effective date

Oct 1, 2026

Identified

Oct 2, 2026

Summary

Independence Blue Cross published an update to its Medicare Advantage medical policy MA11.015ah on bioengineered skin substitutes on 2026-10-01, stating it became effective 10/01/2026, which is already in the past as of today. The lower extremity wound criteria, documentation and billing rules now directly follow CMS criteria, a Biobrane glove was added for second- and third-degree burns, and a long list of HCPCS codes was added as eligible while several CPT codes were marked experimental. Confirm with Independence Blue Cross that this is still the current version before relying on it.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 8 steps

01Already effective 10/01/2026: Billing team should confirm that Medicare Advantage claims for bioengineered skin substitutes follow the revised policy.

02For chronic lower extremity wounds, the chart must document a skin deficit of at least 1.0 cm2, a clean wound without infection, necrosis or exposed bone, adequate circulation (for example ABI of at least 0.60 or toe pressure above 30 mm Hg), and a failed response to appropriate wound care using the CMS definition, with the diagnosis and wound history recorded so the claim matches the criteria.

03Providers and front desk staff should be told that skin substitutes used for acute wounds, post-Mohs, or post-surgical use are treated as experimental or investigational under this policy.

04In charge entry, add the newly eligible HCPCS codes (for example A2005, A2006, the Q4 series, and C9358 to C9364) only for products listed under the applicable indication, and flag CPT 1044T through 1049T as experimental or investigational rather than submitting them as covered.

05Also update the code set for the revised codes A2040 through A2045 and Q4298 and Q4299.

06Biobrane glove is now listed as medically necessary for second- and third-degree burns, so update the burn indication in the charge set-up.

07The HCPCS G0681 through G0684 effective date was revised to 01/01/2026, which has already passed, so confirm those charges use current dates.

08Watch for Independence Blue Cross's next medical policy bulletin.

Codes mentioned

A2001A2002A2004A2005A2006A2007A2020A2029A2040A2041A2042A2043A2045A2046A2047A2048A2049A2050C1832C9358C9360C9364Q4130Q4138Q4142Q4143Q4150Q4207Q4212Q4213Q4223Q4226Q4233Q4240Q4241Q4242Q4243Q4285Q4286Q4298Q4299Q4313Q4315Q4316Q4323Q4324Q4334Q4335Q4343Q4346Q4347Q4348Q4349Q4350Q4351Q4352Q4353Q4360Q4369Q4391G0681G0682G0683G068415011150121501315014

Original notice

MA11.015ah, Bioengineered Skin Substitutes

medpolicy.ibx.com · Always check the source before changing claims.

View original ↗

MA11.015ah, Bioengineered Skin SubstitutesHighEffective Oct 1, 2026 · Medical Policy 12.01.01bv, Experimental/Investigational ServicesMediumEffective Oct 1, 2026 · Medical Policy 11.08.20at, Bioengineered Skin SubstitutesHighEffective Oct 1, 2026 · Medical Policy 11.08.20at, Bioengineered Skin SubstitutesHighEffective Oct 1, 2026 · Medical Policy Browse every Independence Blue Cross change in the policy list

MA11.015ah, Bioengineered Skin Substitutes

Summary

Get alerts when payers change rules like this one

What to do

Codes mentioned

Original notice

Related changes

Related policy hubs

One workspace for payer rules, prior auth, coding and compliance